Nutrition guidelines state that multiple eating patterns are effective for type 2 diabetes and that therapy should be individualized. Yet many nutrition plans fail to account for interpersonal variability in blood glucose response to meals. This diminishes the ability of dietary interventions to optimize glycemic control and may lessen patient satisfaction, self--efficacy, and adherence. Continuous glucose monitoring (CGM) can facilitate behavior change in type 2 diabetes and has been associated with improved outcomes in nutrition intervention studies; this literature is limited by small study sample sizes and heterogeneity of study design and outcomes, and more data are needed. CGM could be a powerful tool for adapting a nutrition plan based on blood glucose response at an individual level. This study will test the use of CGM to personalize nutrition therapy compared to nutrition therapy alone (without CGM) for participants with type 2 diabetes who are not meeting glycemic treatment goals.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Enrollment
8
will receive evidence-based nutrition guidance by a certified and licensed registered dietitian (RD), including information on portion sizes, macronutrient types, and effect of carbohydrates on blood glucose. will receive Dexcom G6 Pro CGMs to wear throughout the study. The CGM will be unblinded so that the glucose data will be available in real time to the participant and investigators. The dietitian and participant will review CGM data together
will receive evidence-based nutrition guidance by a certified and licensed registered dietitian (RD), including information on portion sizes, macronutrient types, and effect of carbohydrates on blood glucose.
University of Minnesota
Minneapolis, Minnesota, United States
HgbA1c
Time frame: week 12
Glucose variability/coefficient of variation
using CGM data
Time frame: week 12
mean glucose
using CGM data
Time frame: week 12
time in range (glucose 70-180 mg/dl)
using CGM data
Time frame: week 12
time above range (glucose 70-180 mg/dl)
using CGM data
Time frame: week 12
Weight
Time frame: week 12
Fasting plasma glucose
Time frame: week 12
Fasting serum insulin
Time frame: week 12
Serum lipid panel
Time frame: week 12
Intervention Acceptability Questionnaire
Time frame: week 12
Diabetes Treatment Satisfaction Questionnaire (DTSQ)
Time frame: week 12
Diet Satisfaction Questionnaire (DSat-28)
Time frame: week 12
Diabetes Management Self-Efficacy Scale (DMSES)
Time frame: week 12
Medication Effect Score
Time frame: week 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.